Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study-MedSci.cn

Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study

Qin, SK; Li, J; Bai, YX; Shu, YQ; Li, W; Yin, XL; Cheng, Y; Sun, GP; Deng, YH; Zhong, H; Li, YF; Qian, XP; Zhang, LM; Zhang, JD; Chen, KH; Kang, WY

Li, J (corresponding author), Tongji Univ, Dept Med Oncol, Shanghai East Hosp, 1800 Yuntai Rd,Pudong New Area, Shanghai, Peoples R China.

BIODRUGS, 2021; 35 (4): 445

Abstract

Plain Language Summary Colorectal cancer (CRC) is the third most common cancer worldwide. Approximately 20% of patients with CRC have metastases at th......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study

科室

工具

服务